Previous Close | 1.3400 |
Open | 1.3328 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 1.2700 - 1.3686 |
52 Week Range | 0.1510 - 1.5600 |
Volume | |
Avg. Volume | 118,974 |
Market Cap | 88.44M |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Jun 25, 2024 - Jul 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.48 |
Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions ...
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable stable disease (SD) in 3 melanoma patients for 6 to 18 months with concomitant tumor shrinkage With response rate and clinical benefit rate increasing to 29% and 50% (4 PR, 3 SD), respectively, MDNA11 continues to demonstrate compelling single-agent activity in the ABILITY-1 stud
MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity MDNA113 is our most advanced pre-clinical candidate that targets IL-13Rα2, a tumor associated antigen, which is overexpressed by immunologically “cold” tumors with high unmet needs in pancreatic, prostate, ovarian, breast